Drugs that potentially could purge the body of so-called senescent cells — thought to play a role in aging — helped Peninsula company snare a $116 million Series B round from a wide range of investors, including Amazon founder and CEO Jeff Bezos' investment arm.
Join the conversation: Follow @SFBusinessTimes on Twitter, "Like" us on Facebook and sign up for our free email newsletters.
Unity Biotechnology Inc., which also named biotech veteran Keith Leonard as CEO, plans to use the cash to take…
Drugs that potentially could purge the body of so-called senescent cells — thought to play a role in aging — helped Peninsula company snare a $116 million Series B round from a wide range of investors, including Amazon founder and CEO Jeff Bezos' investment arm.
Join the conversation: Follow @SFBusinessTimes on Twitter, "Like" us on Facebook and sign up for our free email newsletters.
Unity Biotechnology Inc., which also named biotech veteran Keith Leonard as CEO, plans to use the cash to take…